SCHEMBL4773494

SCHEMBL4773494

NC(Cc1ccccc1F)C(=O)N1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 8/20 0.55
CYP3A4 P08684 3/20 0.55
KDM4E B2RXH2 4/20 0.52
ALOX15 P16050 1/20 0.52
FAP Q12884 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
DPP9 Q86TI2 1/20 0.51
RIPK1 Q13546 1/20 0.50
ALDH1A1 P00352 3/20 0.48
LMNA P02545 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NLN Q9BYT8 2/20 0.47
HDAC8 Q9BY41 1/20 0.46
BLM P54132 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770733 0.85 L3MBTL1 (0.54) DPP4CYP3A4KDM4EFAPDPP8
SCHEMBL4775342 0.85 AKT1 (0.57) DPP4CYP3A4KDM4EALDH1A1LMNA
SCHEMBL4779980 0.84 ALDH1A1 (0.62) DPP4CYP3A4KDM4EALOX15FAP
SCHEMBL4778799 0.82 KMT2A (0.59) DPP4KDM4EFAPDPP8DPP9
SCHEMBL4770161 0.82 DPP4 (0.59) DPP4KDM4EFAPDPP8DPP9
SCHEMBL4772716 0.82 AKT1 (0.57) DPP4CYP3A4HDAC8
SCHEMBL6052885 0.81 NLN (0.59) DPP4FAPDPP8DPP9NLN
SCHEMBL6165188 0.81 NLN (0.59) DPP4FAPDPP8DPP9NLN
Hydrochloric Acid SCHEMBL6163223 0.80 NLN (0.58) DPP4FAPDPP8DPP9NLN
Hydrochloric Acid SCHEMBL6163217 0.80 NLN (0.58) DPP4FAPDPP8DPP9NLN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 DPP4 616/4885CYP3A4 1320/4885KDM4E 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.